Myrio Tx publishes in Cancer Cell

6^th June, 2025 

Key Highlights 

• Myrio Tx and the University of Pennsylvania’s (UPenn) enduring partnership drives innovation in KRAS based cell therapy for solid tumours  

• Myrio Tx’s precision scFv antibodies provided the foundation for UPenn’s NeoCARs. Yielding promising animal model results: Now live in Cancer Cell: https://doi.org/10.1016/j.ccell.2025.05.006 

• Remarkably, all mice in the treatment arm achieved complete response (CR) and 100% survival throughout the 60-day study. No toxicity or tumour progression was observed, unlike the control groups 

Myrio Tx and University of Pennsylvania’s long standing collaboration has yielded compelling results in developing first-in-class and best-in-class next-generation cancer therapies for solid tumours recently published in Cancer Cell: https://doi.org/10.1016/j.ccell.2025.05.006 

Approximately 20% of all solid tumours possess a mutation in the KRAS gene (mKRAS), and as such mKRAS presents a unique and attractive signature for cancer targeting.  

Myrio Tx has developed a series of scFv antibodies that precisely target mKRAS. These binders easily discriminate between wildtype and mKRAS, boasting high affinity binding (K_d values from 3-22 nM)  resulting in potency and specificity in cancer cell killing in vitro. 

These potent and specific scFvs were integrated into the next-generation CAR-T platform – NeoCARs from University of Pennsylvania. Novel enhancements were also leveraged- TCR Knock-Out, to prevent graft-versus-host disease and cellular toxicity; and inducible IL-12-IFN-g cytokines, to boost tumour-killing activity . The safety and potency of this mKRAS anti-cancer therapy was demonstrated in human-tumour mice models, with all animals in this treatment group showing complete response and survival for the duration of the 60-day experiment, exhibiting zero tumor progression or toxicity – in stark contrast to all the other control groups. 

These results powerfully demonstrate the precision, effectiveness and potency of Myrio Tx’s antibody engineering platform and their application in translational immune-oncology, making the next-generation of precision immuno-oncology therapeutics closer to patients.